Showing results (51-60 of 464) with videos related to
Sort By:
Pageof 47
Rheumatology (Oxford, England)|February 27, 2019
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritisGeorge E Fragoulis, Iain B McInnes, Stefan SiebertJournal of Clinical Periodontology|February 18, 2011
What can the periodontal community learn from the pathophysiology of rheumatoid arthritis?Shauna Culshaw, Iain B McInnes, Foo Y LiewSeminars in Arthritis and Rheumatism|October 26, 2013
Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeuticsWim B van den Berg, Iain B McInnesLancet (London, England)|May 10, 2016
Rheumatoid arthritisJosef S Smolen, Daniel Aletaha, Iain B McInnesArthritis Research & Therapy|March 4, 2005
Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?David W McCarey, Naveed Sattar, Iain B McInnesAnnals of the Rheumatic Diseases|August 27, 2021
Message from the new EULAR President and Steering GroupAnnamaria Iagnocco, Daniel Aletaha, Xenofon Baraliakos, et al.Arthritis Research & Therapy|January 12, 2005
Interleukin-18: a therapeutic target in rheumatoid arthritis?Iain B McInnes, Foo Y Liew, J Alastair GracieClinical and Experimental Rheumatology|October 8, 2014
Targeting the P2X7 receptor in rheumatoid arthritis: biological rationale for P2X7 antagonismIain B McInnes, Simon Cruwys, Keith Bowers, et al.Modern Rheumatology|March 19, 2021
Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trialsYoshiya Tanaka, Arthur Kavanaugh, Jason Wicklund, et al.Journal of Leukocyte Biology|January 30, 2003
Interleukin-18J Alastair Gracie, Susan E Robertson, Iain B McInnesPageof 47